2034. Outcomes with ceftazidime/avibactam in patients with carbapenem-resistant Pseudomonas infections: a multi-center study
Session: Poster Abstract Session: Antimicrobial Resistant Infections: Treatment
Saturday, October 29, 2016
Room: Poster Hall
  • CAZAVI for Pseudomons ID week 2016.pdf (375.4 kB)
  • Background: Ceftazidime-avibactam (CAZAVI) is a cephalosporin-beta-lactamase inhibitor combination that is active against Enterobacteriaceae and Pseudomonas aeruginosa that is resistant to other agents, including carbapenems and late-generation cephalosporins. This purpose of this study is to describe the outcomes of patients receiving ceftazidime-avibactam for Pseudomonas infections.

    Methods: A retrospective chart review was completed from March 2015 through April 2016 at 3 hospitals in the United States for adult patients who received ceftazidime/avibactam for a Pseudomonas infection. Patients were included if they received CAZAVI for at least 24 hours for a carbapenem-resistant Pseudomonas. Dosage was chosen by providers at individual sites. The primary outcome was in-hospital mortality. Microbiologic and clinical outcomes were also evaluated. Microbiological success required a negative culture at the end of therapy. Clinical success was judged by improved symptoms, improved imaging where relevant, and defervesence.



    Results (N=10)

    Male gender, n(%)

    7 (70)

    Age (median, IQR)

    72.5 (70-74.5)

    Charlson Comorbidity Index (median, IQR)

    6 (4-7.75)

    Pitt Bacteremia Score (median, IQR)

    2 (0.25-2)

    ICU, n(%)

    7 (10)

    Moderate-severe renal disease

    4 (40)

    Moderate-severe liver disease

    0 (0)

    Primary infection, n(%)



    Urinary tract




    5 (50)

    1 (10)

    1 (10)

    1 (10)

    1 (10)

    1 (10)

    Hospital day CRE infection diagnosed (median, IQR)

    1.5 (1-23)

    Hospital day CAZAVI started (median, IQR)

    6.5 (2-25)

    Patients receiving concomitant therapy for index pathogen, n(%)

    5 (50)

    Isolates susceptible to CAZAVI, n/N (%)

    7/7 (100)

    In-hospital mortality, n(%)

    2 (20)

    Cure or presumed microbiologic cure, n(%)

    9 (90)

    Clinical success, n(%)

    8 (80)

    Conclusion: In this severely ill population, 90% of patients had presumed cure, 80% had clinical success, and 80% were alive at the end of their hospital stay. Ceftazidime/avibactam is a potential option for patients with multi-drug resistant organisms causing Pseudomonas infections, including those in intensive care.

    Madeline King, PharmD, Temple University School of Pharmacy, Philadelphia, PA, Vanthida Huang, PharmD, Midwestern University College of Pharmacy-Glendale, Glendale, AZ, Jason Gallagher, PharmD, FCCP, FIDSA, BCPS, Temple University, Philadelphia, PA and Emily Heil, PharmD, Pharmacy Practice and Science, University of Maryland School of Pharmacy, Baltimore, MD


    M. King, None

    V. Huang, None

    J. Gallagher, Allergan: Scientific Advisor and Speaker's Bureau , Consulting fee and Speaker honorarium
    Merck: Scientific Advisor and Speaker's Bureau , Consulting fee and Speaker honorarium
    Astellas: Scientific Advisor and Speaker's Bureau , Consulting fee and Speaker honorarium

    E. Heil, None

    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.